Carduso Capital will be investing in the
PureIMS Twincer dry powder inhaler
product has so much potential that time to invest is precious,’
says Jan de Vries, director of the health care company IMDS in Roden and co-producer of the
Twincer in Dagblad van het Noorden (DVHN).
The Twincer and Cyclops Twincer inventions were made by UG employees, and are legally owned by UG.
Koos Koops, Carduso Capital fund manager, is excited of the investment: ‘This product has the potential to be marketed in very short time.’ Carduso Capital participates in technology companies based on scientific knowledge from the University of Groningen and the UMCG.
De Vries is excited about the benefits of inhaling drugs via the innovative dry powder inhaler : ‘Inhaling medicines through the lungs has many advantages: it is an effective method to gain access to the body through the lungs. Secondly, the route via the airways offers many advantages over the gastro-intestinal-tract, for example because drug degrading enzymes are omitted and absorption is faster. Furthermore, the administration via the lung is less painfull and easier than an injection,’ stresses De Vries in DVHN. Pure-IMS is the licensee of two patents of the University of Groningen: Twincer dating from 2003 and Cyclops Twincer dating from 2014.
In general, UG/UMCG patents inventions which comply with the criteria for patenting (new and inventive), and which potentially have commercial value. For further development, co-operation with a commercial partner is usually sought. A license (or purchase) contract is negotiated on a case-by-case basis. With respect to financial compensation for UG/UMCG, it typically includes terms on (1) take-over of future patent costs, (2) reimbursement of historical patent costs, and (3) royalty and/or milestone payments, based on the market value of the invention. In case of success, net patent income will flow to UG/UMCG, usually on the long term. This income is distributed between inventors, research group, faculty and the central Patent Fund. The latter fund is used to finance new patent applications of UG/UMCG, and functions as a “revolving fund”.
Prof. Erik Frijlink, Pharmaceutical Technology and Biopharmacy, UG, is one of the f ounding fathers of the Twincer invention. The Frijlink team has been supported by the University Patent Policy and is really proud of the results of the Twincer concept for better ways to inhale drugs Frijlink: ‘And the Twincer concept is just a start. Currently, we are (amongst others) developing a new pulmonary therapy to treat Parkinson’s disease, a challenging project with a huge potential to improve the quality of life of the patients. This project just entered its clinical development phase.’
The Cabinet’s decision, based on the advice of the Van Rijn committee, will have disastrous consequences for the University of Groningen as a broad-based classical university.
The University of Groningen (UG) holds the 114th place in the QS World University Rankings. The QS Ranking is an influential ranking list of almost 1,000 universities worldwide. Last year the UG held the120th place.
Out of the 25 entries for the Dutch Huibregtsen Prize, the jury has nominated six scientific research projects. UG professor Pauline Westerman and Cisca Wijmenga, Rector Magnificus of the UG as of 1 September 2019, are two of the six nominees for the...